Lindbrook Capital’s Elicio Therapeutics ELTX Stock Holding History

Lindbrook Capital’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3	Closed	–	–	2108
2021 Q3	$0	Buy	+3	New	+$324	﹤0.01%	1888

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lindbrook Capital's ELTX Position: Q4 2021 in Review

Lindbrook Capital sold out of Elicio Therapeutics (ELTX) in Q4 2021, closing a stake of 3 shares.

Lindbrook Capital first reported a position in ELTX in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 53 funds tracked by Wall St. Rank hold ELTX as of Q4 2021.

Lindbrook Capital reported no remaining Elicio Therapeutics position as of Q4 2021 after selling out during the quarter.
Lindbrook Capital sold 3 Elicio Therapeutics shares in Q4 2021.
Lindbrook Capital first reported a position in Elicio Therapeutics in Q3 2021 and held it in 1 quarter.
Lindbrook Capital's Elicio Therapeutics position peaked at $0 in Q3 2021.
53 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2021.

Based on Lindbrook Capital's 13F filing for Q4 2021, filed 18 Jan 2022.